Authors Year Medication Disease Predictive of (while on therapy) Predictive of (after drug withdrawal) Relapse Risk (when available) Sustained remission Relapse Risk (when available) Sustained remission
Hawthorne et al. [12 ]
1992
Azathioprine
UC HR (one year older): 0.95; 95% CI: 0.93–0.98 Older age HR: 0.97; 95% CI: 0.93–1.01; Longer duration of remission at entry
Cassinotti et al. [27 ]
2009
Azathioprine
UC Concomitant aminosalicylates Duration of azathioprine therapy (3–6 months versus >48 months) HR: 2.78; 95% CI: 1.27–6.11 No remission versus remission HR: 2.35; 95% CI: 1.43–3.85 Disease extent: left sided versus extensive colitis HR: 1.79; 95% CI: 1.06–3.02 Proctosigmoiditis versus extensive colitis HR: 2.02; 95% CI: 1.10–3.72
Bouhnik et al. [16 ]
1996
Thiopurine
CD Female gender RR: 2.3; 95% CI: 1.0–5.1 Male gender RR: 5.2; 95% CI: 2.2–12.0 Age of ≤26 years RR: 2.5; 95% CI: 1.3–4.5 Duration of remission (<4 years) RR: 6.6; 95% CI: 2.7–16.2
Lémann et al. [15 ]
2005
Azathioprine
CD CRP ≥ 20 mg/L RR: 16.9; 95% CI: 2.7–104.3 Hemoglobin ≤ 12 g/dL RR: 8.7; 95% CI: 1.6–48.8 Longer time without steroids (≥50 months) RR: 5.2; 95% CI: 1.5–18.1
Treton et al. [18 ]
2009
Azathioprine
CD CRP ≥ 20 mg/L HR: 58.6; 95% CI: 7.5–457 Neutrophil count ≥ 4 × 109 /L HR: 3.2; 95% CI: 1.6–6.3 Hemoglobin ≤ 12 g/dL HR: 4.8; 95% CI: 1.7–13.7
Kim et al. [28 ]
1999
6-Mercaptopurine
CD Younger age 1 year increase in age = 2.8% decrease of HR (95% CI: 1.0–4.8%) Higher mercaptopurine doses 1 mg increase in remission doses = 1.8% increase of HR 1.8% (95% CI: 0.7–2.8%) Farkas et al. [24 ] 2013 Infliximab UC Previous cycle of infliximab therapy
Domènech et al. [20 ]
2005
Infliximab
CD Partial response in luminal CD after three infusions Perianal disease in luminal and perianal CD after 1 year treatment Steenholdt et al. [30 ] 2012 Infliximab CD Longer disease duration at first infusion (median: 7 vs. 5 yrs) HR: 1.1; 95% CI: 1.0–1.1
Louis et al. [22 ] 2012 Infliximab CD Male gender HR: 3.7; 95% CI: 1.9–7.4 Corticosteroid use in the preceding 6–12 months HR: 3.5; 95% CI: 1.1–10.7 Infliximab trough levels ≥ 2 mg/mL HR: 2.5; 95% CI: 1.1–5.4 CDEIS > 0 HR: 2.3; 95% CI: 1.1–4.9 Leukocyte count > 6 × 109 /L HR: 2.4; 95% CI: 1.2–4.7 Hemoglobin ≤ 145 g/L HR: 6.0; 95% CI: 2.2–16.5 CRP ≥ 5 mg/L HR: 3.2; 95% CI: 1.6–6.4 Fecal calprotectin ≥ 300 μ g/g HR: 2.5; 95% CI: 1.1–5.8 Absence of surgical resection HR: 4.0; 95% CI: 1.4–11.4 Molnár et al. [23 ] 2013 Infliximab or adalimumab CD Previous biological therapy OR: 4.23; 95% CI: 1.39–12.84 Dose-intensification during the 1-year anti-TNF therapy OR: 12.96; 95% CI: 1.39–120.5 Corticosteroid use at the beginning of anti-TNF therapy (in patients not receiving steroids) Smoking status (in patients not receiving steroids) Male gender (if patients with dose-intensification are excluded) OR: 2.92; 95% CI: 1.06–8.2
